Categories Earnings, Health Care

Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot

— Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of 2019, compared to a loss of $6.1 million or $0.85 per share last year. Analysts had forecast a loss of $0.61 per share.

— Being a development-stage biopharmaceutical company, Catabasis did nor record revenues in the December-quarter

— Research & Development expenses increased 16% year-over-year to $4.3 million during the three-month period

— At $2.5 million, selling, general and administrative expenses were up 4% from the year-ago period

— As of December 2019, cash, cash equivalents and short-term investments were $36.2 million, compared to $40.6 million as of September 2019

— Expects to fund operations through a potential NDA filing and into the third quarter of 2021, using available cash

— Expects to publish top results from the phase-3 PolarisDMD trial of edasalonexent, in Duchenne muscular dystrophy, in the fourth quarter of 2020

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Key highlights from Hormel Foods’ (HRL) Q1 2024 earnings results

Hormel Foods Corporation (NYSE: HRL) reported first quarter 2024 earnings results today. Net sales were $3 billion, up 1% from the same period last year. Net earnings attributable to Hormel

HP Earnings: All you need to know about HP Inc.’s Q1 2024 earnings results

HP Inc. (NYSE: HPQ) reported first quarter 2024 earnings results today. Net revenue of $13.2 billion was down 4.4% from the same period a year ago. GAAP net earnings were

CRM Earnings: Salesforce Q4 2024 profit and revenue beat estimates

Customer relationship management platform Salesforce, Inc. (NYSE: CRM) reported higher earnings and revenues for the fourth quarter of 2024. The results also topped expectations. Fourth-quarter profit, excluding non-recurring items, increased

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top